We found that OIT3 was downregulated in HCC tissues, and its expression level was significantly associated with clinical outcomes, suggesting it is a potential novel biomarker for the diagnosis and prognosis of HCC patients. Here, OIT3 is linked to hepatocellular carcinoma.